Bone Marrow TransplantIncyte Corporation INCB-18424-MA-GD-301

CONDITION(S): Graft-versus-host Disease (GVHD) - TRIAL: Incyte Corporation INCB-18424-MA-GD-301 - An Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant

To provide ruxolitinib through an expanded access program for the treatment of graft-versus-host disease (GVHD) in United States to patients who are ineligible or unable to participate in any actively enrolling Incyte-sponsored clinical studies for ruxolitinib in the treatment of GVHD.

Drug

Ruxolitinib

Trial Type

Interventional

Condition

Graft Versus Host Disease (GVHD)